Latest Insider Transactions at Janux Therapeutics, Inc. (JANX)
This section provides a real-time view of insider transactions for Janux Therapeutics, Inc. (JANX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Janux Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Janux Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2024
|
Jay Lichter |
SELL
Open market or private sale
|
Indirect |
1,500,000
-17.15%
|
$81,000,000
$54.75 P/Share
|
|
Jun 03
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
822,721
-17.15%
|
$44,426,934
$54.75 P/Share
|
|
Jun 03
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
677,279
-17.15%
|
$36,573,066
$54.75 P/Share
|
|
Jun 03
2024
|
Tighe Reardon Acting Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
822,721
-17.15%
|
$44,426,934
$54.75 P/Share
|
|
Feb 29
2024
|
Avalon Ventures Xi, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
577,478
-64.0%
|
-
|
|
Feb 29
2024
|
Avalon Ventures Xi, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
44,544
+50.0%
|
-
|
|
Feb 29
2024
|
Avalon Ventures Xi, L.P. |
SELL
Other acquisition or disposition
|
Direct |
438,722
-10.0%
|
-
|
|
Feb 29
2024
|
Sheila Gujrathi |
BUY
Other acquisition or disposition
|
Direct |
2,986
+2.69%
|
-
|
|
Feb 29
2024
|
Vickie L Capps |
BUY
Other acquisition or disposition
|
Direct |
1,493
+2.23%
|
-
|
|
Nov 13
2023
|
Jay Lichter |
BUY
Open market or private purchase
|
Indirect |
849,854
+50.0%
|
$4,249,270
$5.87 P/Share
|
|
Nov 13
2023
|
Tighe Reardon Acting Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
849,854
+50.0%
|
$4,249,270
$5.87 P/Share
|
|
Nov 13
2023
|
Avalon Ventures Xi, L.P. |
BUY
Open market or private purchase
|
Indirect |
849,854
+50.0%
|
$4,249,270
$5.87 P/Share
|
|
Jul 19
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
495,008
+5.75%
|
$5,940,096
$12.46 P/Share
|
|
Dec 29
2021
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
40,400
-1.59%
|
$808,000
$20.3 P/Share
|
|
Dec 29
2021
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
40,400
-1.59%
|
$808,000
$20.3 P/Share
|
|
Dec 21
2021
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
119,400
-4.51%
|
$2,268,600
$19.0 P/Share
|
|
Dec 21
2021
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
119,400
-4.51%
|
$2,268,600
$19.0 P/Share
|
|
Dec 16
2021
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
393,300
-12.93%
|
$7,472,700
$19.07 P/Share
|
|
Dec 16
2021
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
393,300
-12.93%
|
$7,472,700
$19.07 P/Share
|
|
Jun 15
2021
|
Avalon Ventures Xi, L.P. |
BUY
Open market or private purchase
|
Indirect |
629,411
+12.32%
|
$10,699,987
$17.0 P/Share
|
|
Jun 15
2021
|
Avalon Ventures Xi, L.P. |
BUY
Conversion of derivative security
|
Indirect |
3,850,081
+36.52%
|
-
|
|
Jun 15
2021
|
Avalon Ventures Xi, L.P. |
BUY
Conversion of derivative security
|
Direct |
4,195,067
+32.84%
|
-
|
|
Jun 15
2021
|
Jay Lichter |
BUY
Open market or private purchase
|
Indirect |
629,411
+12.32%
|
$10,699,987
$17.0 P/Share
|
|
Jun 15
2021
|
Jay Lichter |
BUY
Conversion of derivative security
|
Indirect |
8,045,148
+34.31%
|
-
|
|
Jun 15
2021
|
Tighe Reardon Acting Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
629,411
+12.32%
|
$10,699,987
$17.0 P/Share
|
|
Jun 15
2021
|
Tighe Reardon Acting Chief Financial Officer |
BUY
Conversion of derivative security
|
Indirect |
3,850,081
+36.52%
|
-
|
|
Jun 15
2021
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
705,853
+23.49%
|
$11,999,501
$17.0 P/Share
|
|
Jun 15
2021
|
Peter A. Thompson Director |
BUY
Conversion of derivative security
|
Indirect |
2,336,911
+42.5%
|
-
|
|
Jun 15
2021
|
Bregua Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
58,823
+1.54%
|
$999,991
$17.0 P/Share
|
|
Jun 15
2021
|
Bregua Corp > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,690,427
+27.43%
|
-
|
|
Jun 15
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
705,853
+23.49%
|
$11,999,501
$17.0 P/Share
|
|
Jun 15
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,336,911
+42.5%
|
-
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
2,941,176
+20.9%
|
$49,999,992
$17.0 P/Share
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
5,729,468
+44.64%
|
-
|